Who are Vonoprazan, Amoxicillin and Clarithromycin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vonoprazan-amoxicillin-and-clarithromycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vonoprazan, Amoxicillin and Clarithromycin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vonoprazan, Amoxicillin and Clarithromycin (Vonoprazan, Amoxicillin and Clarithromycin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic + macrolide antibiotic combination. Area: Gastroenterology /

marketed Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic + macrolide antibiotic combination H+/K+-ATPase (vonoprazan); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin) Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Vonoprazan, Amoxicillin and Clarithromycin (Vonoprazan, Amoxicillin and Clarithromycin) — Kaohsiung Medical University. This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid (vonoprazan) while simultaneously killing the bacteria with two antibiotics (amoxicillin and clarithromycin).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vonoprazan, Amoxicillin and Clarithromycin TARGET	Vonoprazan, Amoxicillin and Clarithromycin	Kaohsiung Medical University	marketed	Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic + macrolide antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic + macrolide antibiotic combination class)

Kaohsiung Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vonoprazan, Amoxicillin and Clarithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/vonoprazan-amoxicillin-and-clarithromycin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab